Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin–norepinephrine reuptake inhibitor

Author： Nichols Alice I Tourian Karen A Tse Susanna Y Paul Jeffrey

Publisher： Informa Healthcare

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.6, Iss.12, 2010-12, pp. : 1565-1574

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A randomised, double‐blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine†

Human Psychopharmacology: Clinical And Experimental (Electronic), Vol. 30, Iss. 4, 2015-07 ,pp. : 327-327

John Wiley & Sons Inc

Access to resources Recommend Favorite

Desvenlafaxine succinate for the treatment of major depressive disorder

By Lohoff Falk W Rickels Karl

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 12, 2008-08 ,pp. : 2129-2136

Informa Healthcare

Access to resources Recommend Favorite

Serotonin-Norepinephrine Reuptake Inhibitor Antidepressants and the Risk of Falls in Older People: Case-Control and Case-Series Analysis of a Large UK Primary Care Database

By Gribbin Jonathan

Drugs & Aging, Vol. 28, Iss. 11, 2011-11 ,pp. : 895-902

Adis International

Access to resources Recommend Favorite

Therapy-Resistant Psychotic-Depressive Disorder: Remission with a Selective Serotonin Reuptake Inhibitor in Combination with Olanzapine

By Braus D.F.

Clinical Drug Investigation, Vol. 20, Iss. 6, 2000-12 ,pp. : 455-459

Adis International

Access to resources Recommend Favorite

Serotonin-Norepinephrine Reuptake Inhibitors for Pain Control: Premise and Promise

Current Neuropharmacology, Vol. 7, Iss. 4, 2009-12 ,pp. : 331-336

Bentham Science Publishers

Access to resources Recommend Favorite